Esco2 and cohesin regulate CRL4 ubiquitin ligase ddb1 expression and thalidomide teratogenicity. Issue 5 (4th March 2022)

• Record Type: Journal Article
• Authors: Sanchez, Annie C.; Thren, Elise D.; Iovine, M. Kathryn; Skibbens, Robert V.
• Is Part Of: Cell cycle. Volume 21:Issue 5(2022)
• Page Start: 501
• Page End: 513
• Publication Date: 2022-03-04
• Subjects: Roberts syndrome (RBS) -- cornelia de lange syndrome (Cdls) -- cohesinopathies -- thalidomide -- birth defects -- CRL4 ubiquitin ligase; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2021.2023304
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Cornelia de Lange syndrome (CdLS) and Roberts syndrome (RBS) are severe developmental maladies that arise from mutation of cohesin (including SMC3, CdLS) and ESCO2 (RBS). Though ESCO2 activates cohesin, CdLS and RBS etiologies are currently considered non-synonymous and for which pharmacological treatments are unavailable. Here, we identify a unifying mechanism that integrates these genetic maladies to pharmacologically-induced teratogenicity via thalidomide. Our results reveal that Esco2 and cohesin co-regulate the transcription of a component of CRL4 ubiquitin ligase through which thalidomide exerts teratogenic effects. These findings are the first to link RBS and CdLS to thalidomide teratogenicity and offer new insights into treatments.